Effect of pentoxifylline on histopathological changes in steroid-induced osteonecrosis of femoral head: experimental study in chicken
Pentoxifylline (PTX) is a derivative of methylxanthine and is used in peripheral vascular and cerebrovascular diseases for its effect on the regulation of blood circulation. We investigated whether PTX could be beneficial for femoral head osteonecrosis associated with steroid through these effects.
Sixty mature Leghorn type chickens were chosen and divided into three groups. The 25 chickens in group A were given a weekly dose of 3 mg/kg/week methylprednisolone acetate intramuscularly. Four chickens in group B died after the first drug injection and were excluded from the study. Therefore, the remaining 21 chickens in group B were additionally given 25 mg/kg/day pentoxifylline intramuscularly, along with the steroid medication as given in group A. The ten chickens in group C were not given any injections, as they were accepted as the control group. After the sacrifice of the animals at week 14, both femoral heads were taken from each animal. The animals which died along the course of the study also underwent pathological examination but were not a part of the statistical analysis.
In this study, steroid induced femoral head osteonecrosis has been experimentally observed in chickens after high doses of corticosteroid therapy. The chickens were given pentoxifylline in order to prevent the effects of steroid on bones and bone marrow. The results showed that chickens are suitable osteonecrosis models, and that steroid causes adipogenesis and necrosis in the bone marrow and the death of the subchondral bone.
The results of this study hint at the assumption that PTX may have a positive benefit on ONFH. PTX seems to minimise the effects of the steroid and reduce the incidence of ONFH.
- 4.Weinstein RS (2011) Glucocorticoid-induced osteonecrosis. Endocrine Dec 15. [Epub ahead of print]Google Scholar
- 7.Jones LC, Hungerford DS (1984) Models of ischemic necrosis of bone. In: Arlet J, Ficat RP, Hungerford DS (eds) Bone circulation. Williams and Wilkins, Baltimore, pp 30–34Google Scholar
- 8.Kawai K, Maruno H, Hirohata K (1983) Fat necrosis of osteocytes as a causative factor in idiopathic osteonecrosis of the femoral head in man. Trans Orthop Res Soc 8:263Google Scholar
- 9.Wang GJ, Sweet DE, Reger SI et al (1977) Fatcell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg 59A:729–735Google Scholar
- 12.Wang GJ, Dughman SS, Reger SI (1984) Femoral head blood flow in long- term steroid treatment (study of rabbit model). In: Arlet J, Ficat RP, Hungerford DS (eds) Bone circulation. Williams and Wilkins, Baltimore, pp 35–37Google Scholar
- 28.Rawadi G, Ferrer C, Spinella-Jaegle S et al (2001) 1-(5-oxohexyl)-3,7-dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 142(11):4673–4682PubMedCrossRefGoogle Scholar
- 30.Horiuchi H, Saito N, Kinoshita T et al (2004) Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline. J Bone Miner Metab 22(4):329–334PubMedCrossRefGoogle Scholar
- 39.Gangji V, Hauzeur JP (2005) Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique. J Bone Joint Surg Am 87 Suppl 1(Pt 1):106–112Google Scholar
- 45.Sounes J, Griffin M, Malslen C et al (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF α generation from human monocytes by interaction with a low-affinity phosphodiesterase 4 conformer. Br J Pharmacol 118:649–658Google Scholar